ELI LILLY & CO recorded 7,335 prescriptions for its oral weight-loss drug Foundayo in the United States during its fourth week. The uptake lags behind the Wegovy pill from Novo Nordisk, which launched in January with a first-mover advantage. Investors view these oral treatments as expanding the weight-loss market to millions of patients, potentially countering pricing pressure on injectable treatments.

Foundayo Faces Uphill Climb to Meet Sales Targets